NCT02142530View on ClinicalTrials.gov

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

January 31, 2018

Conditions
Non-Hodgkin LymphomaDiffuse Large B-cell LymphomaMantle Cell LymphomaFollicular LymphomaPeripheral T-cell Lymphoma
Interventions
DRUG

Carfilzomib

DRUG

Belinostat

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth-Israel Deaconess Medical Center, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Massachusetts General Hospital

OTHER

NCT02142530 - Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | Biotech Hunter | Biotech Hunter